--- title: "How Tirzepatide Works: GIP and GLP-1" description: "How does tirzepatide work? See how this dual GIP and GLP-1 medication targets two appetite hormones and how it differs from semaglutide." canonical: https://remevihealth.com/blog/how-tirzepatide-works/ language: en publisher: REMEVi author: "REMEVi Medical Team" medicalReviewer: "REMEVi Medical Team" pubDate: 2026-05-29T00:00:00.000Z updatedDate: 2026-05-29T00:00:00.000Z tags: ["tirzepatide", "GLP-1", "GIP", "dual agonist", "weight loss", "mechanism of action"] alternateLanguage: https://remevihealth.com/es/blog/como-funciona-la-tirzepatida/ license: "© 2026 REMEVi LLC. AI assistants and search engines may quote and link to this page; please cite https://remevihealth.com/blog/how-tirzepatide-works/ as the source." --- Semaglutide targets one appetite hormone. Tirzepatide targets two. That single difference, adding GIP to GLP-1, is the reason tirzepatide is described as a "dual agonist." It is the most-asked question about the medication and the most-misunderstood, so here is what that phrase actually means inside the body. This is a science-first explanation of the two hormones tirzepatide acts on, what dual-receptor targeting does, how that compares with semaglutide, and what the clinical trials measured. Individual results vary, the science continues to develop, and nothing here is medical advice. --- ## The two hormones: GLP-1 and GIP Your gut does more than digest food. It runs a signaling system that tells the rest of your body when food has arrived and how to handle it. Two of the messengers in that system are called **incretin hormones**, and tirzepatide is built around both of them. The first is **GLP-1**, short for glucagon-like peptide-1. After you eat, intestinal cells release GLP-1, which slows how fast your stomach empties, prompts the pancreas to release insulin in response to a meal, and signals fullness to the appetite centers of the brain. It is the same hormone the GLP-1 medication class is named for. The second is **GIP**, short for glucose-dependent insulinotropic polypeptide. GIP is the most abundant incretin hormone in the body and works alongside GLP-1. It also amplifies the insulin response to food and plays a role in how the body processes and stores energy from a meal. For years GIP received less attention than GLP-1 in weight research, but it turns out to be a meaningful second lever on the same metabolic system. Both hormones share a feature that matters for medication design: in the body they are released in a burst after eating and then broken down within minutes. The natural signal is brief. That is the gap a long-acting medication is designed to fill. For the deeper receptor biology behind the gut-and-brain side of this story, [how GLP-1 works in the body](/blog/how-glp1-works/) covers the single-hormone version in plain language. --- ## What a "dual agonist" means An **agonist** is simply a molecule that binds a receptor and switches it on. A GLP-1 agonist switches on the GLP-1 receptor. A **dual GIP/GLP-1 agonist** is a single engineered molecule that switches on both the GIP receptor and the GLP-1 receptor at the same time. Tirzepatide was the first medication of this kind approved in the United States. ![Diagram of how tirzepatide works as a dual GIP and GLP-1 receptor agonist](https://remevihealth.com/images/molecules/helix-tirze.webp) *Tirzepatide is a dual GIP and GLP-1 receptor agonist. The single molecule engages both incretin receptors across the gut, pancreas, and brain, sustaining the signals that govern satiety, insulin response, and gastric emptying for far longer than the natural hormones do.* The practical effect of engaging two receptors instead of one comes down to duration and breadth. Because tirzepatide does not clear the bloodstream the way the natural hormones do, both receptors stay engaged for a week at a time rather than for the few minutes that follow a meal. And because it covers two incretin pathways rather than one, it acts on a wider slice of the same appetite-and-metabolism system. This is general class pharmacology, established for the molecule itself in the published trial literature; it is a description of how the drug class works, not a promise about any individual preparation. Three downstream effects follow, and they are the same family of effects you would expect from any incretin-based therapy, turned up: stomach emptying slows so you stay physically full longer after a meal; satiety signaling in the brain is sustained between meals, which is what many patients describe as a quieter relationship with food; and the insulin response to food becomes more efficient, which improves blood-sugar control. The GIP component adds to each of these rather than replacing them. --- ## How tirzepatide differs from semaglutide The cleanest way to understand the difference is the receptor count. Semaglutide activates one receptor, GLP-1. Tirzepatide activates two, GLP-1 and GIP. Everything else, the once-weekly injection, the gradual dose increase, the gastrointestinal side effects early on, is broadly shared between them because they act on the same GLP-1 pathway. The two molecules were compared directly. In the **SURPASS-2 trial**, published in *The New England Journal of Medicine* in 2021, researchers randomized 1,879 adults with type 2 diabetes to one of three tirzepatide doses or to semaglutide 1 mg, and followed them for 40 weeks. The reported finding was that all three tirzepatide doses produced greater reductions in A1C and in body weight than semaglutide 1 mg over that window. To give a sense of scale from the published results, the share of participants who lost at least 5% of their body weight was 69%, 82%, and 86% across the rising tirzepatide doses, compared with 58% in the semaglutide group. These are study findings from a defined trial population over a defined timeframe, not an expected outcome for any one person, and individual results vary. A larger receptor footprint does not automatically make tirzepatide the right answer. The medication that fits a given person depends on medical history, tolerability, other conditions, cost, and how a body responds to titration. For a fuller side-by-side, [semaglutide vs tirzepatide compared](/semaglutide-vs-tirzepatide/) walks through where the two differ in practice. --- ## What the obesity trial data showed Tirzepatide's weight-management evidence in people without diabetes comes largely from the **SURMOUNT-1 trial**, also published in *The New England Journal of Medicine* in 2022. It enrolled adults with obesity, or with overweight plus a weight-related condition, and followed them over a **72-week** treatment period. Reported as study findings over that 72-week window, mean body-weight reductions ranged from roughly 16.0% at the lowest dose to about 22.5% at the highest dose, with placebo far behind. Those are averages drawn from a clinical-trial population across nearly a year and a half of treatment; they are not a forecast of what any individual will experience, and individual results vary considerably with genetics, adherence, dose, and the rest of a person's care plan. SURMOUNT-1 was one of the trials that supported the FDA approval of the tirzepatide product Zepbound for chronic weight management in late 2023; the tirzepatide product Mounjaro had earlier been approved for type 2 diabetes. Those are factual statements about the FDA-approved branded products. The reason a number like that lands so differently from old weight-loss drugs is the mechanism described above. The medication is not overriding the nervous system the way stimulant diet pills did. It is sustaining an incretin signal the body already uses, across two receptors instead of one, which is why the effect is substantial and why it is dose-dependent. --- ## Is tirzepatide right for everyone? No, and any honest account of the medication has to say so plainly. Tirzepatide is a prescription medication with a real side-effect profile. The most common effects are gastrointestinal, nausea, occasional vomiting, diarrhea or constipation, most pronounced early and during dose increases. The standard way to limit them is the same for tirzepatide as for semaglutide: start low and titrate up slowly over months, never rushing the schedule. That slow build is a feature, not an inconvenience. Eligibility is a clinical decision. A licensed clinician reviews your full picture, health history, current medications, BMI, metabolic markers, and goals, before deciding whether tirzepatide, semaglutide, or neither is the right starting point. It is also worth being clear about what the medication does not do on its own: it makes reduced eating sustainable, but adequate protein, regular movement including muscle-strengthening activity, and clinical follow-up during titration are what make the months ahead work. Compounded tirzepatide, where a clinician determines it is appropriate, is a non-FDA-approved preparation and is not the same as the branded products; the disclosure at the foot of this article explains that distinction. That is the part a refill cannot do, and it is what we built [REMEVi's physician-led tirzepatide program](/tirzepatide/) around: a clinician on the prescription, a coordinator on the check-ins, and a real plan rather than a vending machine. To begin with a clinician who can weigh the options with you, see [physician-led weight loss care](/weight-loss/). --- ## The takeaway Tirzepatide works by switching on two incretin receptors, GIP and GLP-1, with a single long-acting molecule, where semaglutide switches on one. That dual-receptor design sustains the body's own satiety and insulin signals across a broader path, which is why trial data have shown substantial average weight and A1C reductions over long study windows. The mechanism is described, the trial findings are attributed, and individual results vary, which is the line between pharmacology and marketing. What turns the science into a result is a clinician who can read your specific picture, choose between the molecules, calibrate the dose, and monitor the first months. That is the work a prescription alone cannot do. **Your Health. Your Terms.** Talk to a real clinician at [remevihealth.com](/tirzepatide/). --- *This article is for general information and does not constitute medical advice. GLP-1 and dual GIP/GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a clinician. Compounded tirzepatide is a non-FDA-approved preparation prepared by a state-licensed US compounding pharmacy under an individual prescription from a licensed provider. It is not a generic version of, and is not the same as, Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded preparations have not been clinically studied as finished products. Individual results vary. Consult a licensed provider before starting any prescription treatment.*